×
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
NASDAQ:BGNE

BeiGene (BGNE) Stock Forecast, Price & News

$133.96
+2.70 (+2.06%)
(As of 05/27/2022 04:00 PM ET)
Add
Compare
Today's Range
$125.00
$133.96
50-Day Range
$121.11
$216.05
52-Week Range
$118.18
$426.56
Volume
191,569 shs
Average Volume
308,141 shs
Market Capitalization
$13.76 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.85
30 days | 90 days | 365 days | Advanced Chart
Receive BGNE News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

BeiGene logo

About BeiGene

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationally. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene, Ltd. has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Beijing, China.

Headlines

BeiGene (NASDAQ:BGNE) Stock Price Down 4%
BeiGene (NASDAQ:BGNE) Shares Gap Up to $131.67
BeiGene Becomes Oversold (BGNE) - Nasdaq
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BGNE
Fax
N/A
Employees
8,200
Year Founded
2010

Sales & Book Value

Annual Sales
$1.18 billion
Book Value
$57.30 per share

Profitability

Net Income
$-1.41 billion
Net Margins
-218.25%
Pretax Margin
-219.11%

Debt

Price-To-Earnings

Miscellaneous

Free Float
93,565,000
Market Cap
$13.76 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/05/2022
Today
5/29/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

1.91 out of 5 stars

Medical Sector

687th out of 1,432 stocks

Pharmaceutical Preparations Industry

327th out of 683 stocks

Analyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -













BeiGene (NASDAQ:BGNE) Frequently Asked Questions

Is BeiGene a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BeiGene stock.
View analyst ratings for BeiGene
or view top-rated stocks.

When is BeiGene's next earnings date?

BeiGene is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for BeiGene
.

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) issued its quarterly earnings data on Thursday, May, 5th. The company reported ($4.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.12) by $0.12. The firm had revenue of $306.60 million for the quarter, compared to analysts' expectations of $300.41 million. BeiGene had a negative net margin of 218.25% and a negative trailing twelve-month return on equity of 40.10%. The business's revenue was down 49.4% on a year-over-year basis.
View BeiGene's earnings history
.

What price target have analysts set for BGNE?

6 Wall Street analysts have issued 12-month target prices for BeiGene's shares. Their forecasts range from $177.00 to $431.00. On average, they anticipate BeiGene's stock price to reach $315.33 in the next twelve months. This suggests a possible upside of 135.4% from the stock's current price.
View analysts' price targets for BeiGene
or view top-rated stocks among Wall Street analysts.

Who are BeiGene's key executives?
BeiGene's management team includes the following people:
  • Mr. John V. Oyler, Co-Founder, Exec. Chairman & CEO (Age 54, Pay $1.41M) (LinkedIn Profile)
  • Dr. Xiaobin Wu Ph.D., Pres, COO & GM of China (Age 60, Pay $1.23M)
  • Dr. Xiaodong Wang Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Non-Exec. Director (Age 59, Pay $4.25M)
  • Dr. Edna Huang M.D., Consultant (Age 49, Pay $749.55k)
  • Ms. Julia Wang, CFO & Principal Accounting Officer (Age 51)
  • Mr. Daniel Maller, VP of Fin. & Accounting
  • Ms. Mi Zhou, Sr. Director of Investor Relations
  • Mr. Kevin C. Mannix, Sr. VP of Investor Relations.
  • Mr. Scott Samuels, Sr. VP & Gen. Counsel
  • Ms. Diana Lee Francis, VP and Global Head of Quality & Regulatory Compliance
What is John V. Oyler's approval rating as BeiGene's CEO?

21 employees have rated BeiGene CEO John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among BeiGene's employees.

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Square (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

When did BeiGene IPO?

(BGNE) raised $126 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

What is BeiGene's stock symbol?

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

Who are BeiGene's major shareholders?

BeiGene's stock is owned by many different retail and institutional investors. Top institutional shareholders include Capital International Investors (6.84%), Baillie Gifford & Co. (4.00%), Primecap Management Co. CA (3.61%), Invesco Ltd. (2.65%), BlackRock Inc. (2.63%) and Capital Group International Inc. CA (1.11%). Company insiders that own BeiGene stock include Amgen Inc, Bros Advisors Lp Baker, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends for BeiGene
.

Which institutional investors are selling BeiGene stock?

BGNE stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Invesco Ltd., Fiera Capital Corp, USS Investment Management Ltd, State Street Corp, Matthews International Capital Management LLC, New York State Common Retirement Fund, and Baillie Gifford & Co.. Company insiders that have sold BeiGene company stock in the last year include Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Timothy Yung-Cheng Chen, and Xiaobin Wu.
View insider buying and selling activity for BeiGene
or view top insider-selling stocks.

Which institutional investors are buying BeiGene stock?

BGNE stock was purchased by a variety of institutional investors in the last quarter, including Capital International Investors, Bridgewater Associates LP, Zeal Asset Management Ltd, Capital Group International Inc. CA , Capital Group Private Client Services Inc., BlackRock Inc., Goldman Sachs Group Inc., and Aaron Wealth Advisors LLC. Company insiders that have bought BeiGene stock in the last two years include Amgen Inc, and Ltd Beigene.
View insider buying and selling activity for BeiGene
or or view top insider-buying stocks.

How do I buy shares of BeiGene?

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BeiGene's stock price today?

One share of BGNE stock can currently be purchased for approximately $133.96.

How much money does BeiGene make?

BeiGene has a market capitalization of $13.76 billion and generates $1.18 billion in revenue each year. The company earns $-1.41 billion in net income (profit) each year or ($20.090010) on an earnings per share basis.

How many employees does BeiGene have?

BeiGene employs 8,200 workers across the globe.

When was BeiGene founded?

BeiGene was founded in 2010.

What is BeiGene's official website?

The official website for BeiGene is www.beigene.com.

How can I contact BeiGene?

BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 861085148500 or via email at [email protected].

This page was last updated on 5/29/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.